<DOC>
	<DOCNO>NCT01591122</DOCNO>
	<brief_summary>The purpose study demonstrate safety effectiveness abiraterone acetate co-administered prednisone patient chemo-naive metastatic castration resistant prostate Cancer ( mCRPC ) .</brief_summary>
	<brief_title>Study Abiraterone Acetate Plus Prednisone Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This multinational , multicenter , randomize ( study drug assign chance ) , double-blind ( neither physician patient know treatment patient receives ) , placebo-controlled ( inactive substance compare drug test whether drug real effect clinical trial ) study . All patient randomly assign 1:1 ratio abiraterone acetate group ( abiraterone acetate prednisone ) placebo group ( placebo prednisone ) . The study consist screen phase ( within 28 day prior randomization Cycle 1 , Day 1 ) , treatment phase ( 28-day cycle disease progression ) , follow-up phase ( patient contact every 3 month Month 60 , focus primarily survival status ) . Patients receive either abiraterone acetate 1,000 mg daily prednisone 5 mg twice daily placebo prednisone 5 mg twice daily .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Has confirm diagnosis adenocarcinoma prostate evidence metastatic disease Prostate cancer progression document PSA progression radiographic progression Asymptomatic mildly symptomatic prostate cancer Surgically medically castrate , testosterone level &lt; 50 ng/dL Previous antiandrogen therapy progression withdrawal ECOG performance status score 0 1 If opiate analgesic cancerrelated pain , treatment must administer within 4 week Cycle 1 Day 1 If radiation therapy treatment primary tumor give , treatment must administer within 6 week Cycle 1 Day 1 If previously treat ketoconazole prostate cancer , duration treatment must great 7 day Life expectancy least 6 month Active infection medical condition would make prednisone ( corticosteroid ) use contraindicate Any chronic medical condition require high dose corticosteroid 5 mg prednisone twice daily Pathological find consistent small cell carcinoma prostate Liver visceral organ metastasis , brain metastasis , malignancy , except nonmelanoma skin cancer , 30 % probability recurrence within 24 month Prior cytotoxic chemotherapy biologic therapy treatment metastatic castrationresistant prostate cancer ( mCRPC ) Radiation radionuclide therapy treatment mCRPC Uncontrolled hypertension , patient history hypertension allow provide blood pressure control anti hypertensive treatment History pituitary adrenal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Metastatic Castration Resistant Prostate Cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Zytiga</keyword>
</DOC>